Pharm Res
protection by glutathione in young lenses. Invest Ophthalmol Vis
adenoviral vector through spray drying. Int J Pharm. 2016;506(1–
2):289–301.
Sci. 2007;48(8):3705–13.
8. Razygraev A, Arutiunian A. Determination of human serum glu-
tathione peroxidase activity, by using hydrogen peroxide and 5, 5′-
dithio-bis (2-nitrobenzoic acid). Klin Lab Diagn. 2006;6:13–6.
9. Ávila F, Ravello N, Zanocco AL, Gamon LF, Davies MJ, Silva E. 3-
Hydroxykynurenine bound to eye lens proteins induces oxidative
modifications in crystalline proteins through a type I photosensitiz-
ing mechanism. Free Radic Biol Med. 2019;141:103–14.
10. Rathore A, Bhambure R, Ghare V. Process analytical technology
(PAT) for biopharmaceutical products. Anal Bioanal Chem.
2010;398(1):137–54.
11. Shah DD, Zhang J, Maity H, Mallela KMG. Effect of photo-
degradation on the structure, stability, aggregation, and function
of an IgG1 monoclonal antibody. Int J Pharm. 2018;547(1–2):438–
49.
12. Patro SY, Freund E, Chang BS. Protein formulation and fill-finish
operations. 2002.
28. Schöneich C. Redox processes of methionine relevant to β-amyloid
oxidation and Alzheimer's disease. Arch Biochem Biophys.
2002;397(2):370–6.
29. Brange J, Havelund S, Hougaard P. Chemical stability of insulin. 2.
Formation of higher molecular weight transformation products
during storage of pharmaceutical preparations. Pharm Res.
1992;9(6):727–34.
30. Platts L, Falconer RJ. Controlling protein stability: mechanisms
revealed using formulations of arginine, glycine and guanidinium
HCl with three globular proteins. Int J Pharm. 2015;486(1–2):131–
5.
31. Platts L, Darby SJ, Falconer RJ. Control of globular protein ther-
mal stability in aqueous formulations by the positively charged ami-
no acid excipients. J Pharm Sci. 2016;105(12):3532–6.
32. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends
in stabilising peptides and proteins in pharmaceutical formulation–
considerations in the choice of excipients. Expert Opinion on Drug
Delivery. 2009;6(11):1219–30.
13. Cromwell ME, Hilario E, Jacobson F. Protein aggregation and
bioprocessing. AAPS J. 2006;8(3):E572–9.
14. Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, et al.
The immunogenicity of antibody aggregates in a novel transgenic
mouse model. Pharm Res. 2015;32(7):2344–59.
15. Freedman MS, Pachner AR. Neutralizing antibodies to biological
therapies: a “touch of gray” vs a “black and white” story. In: AAN
Enterprises. 2007.
16. Calabresi P, Giovannoni G, Confavreux C, Galetta S, Havrdova E,
Hutchinson M, et al. The incidence and significance of anti-
natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology. 2007;69(14):1391–403.
17. Br B, Bessa J, Folzer E, Ríos Quiroz A, Schmidt R, Bulau P, et al.
Extensive chemical modifications in the primary protein structure
of IgG1 subvisible particles are necessary for breaking immune
tolerance. Mol Pharm. 2017;14(4):1292–9.
18. Doessegger L, Mahler H-C, Szczesny P, Rockstroh H, Kallmeyer
G, Langenkamp A, et al. The potential clinical relevance of visible
particles in parenteral drugs. J Pharm Sci. 2012;101(8):2635–44.
19. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ,
Middaugh CR, Winter G, et al. Overlooking subvisible particles
in therapeutic protein products: gaps that may compromise prod-
uct quality. J Pharm Sci. 2009;98(4):1201–5.
20. Du C, Barnett G, Borwankar A, Lewandowski A, Singh N, Ghose
S, et al. Protection of therapeutic antibodies from visible light in-
duced degradation: use safe light in manufacturing and storage. Eur
J Pharm Biopharm. 2018;127:37–43.
21. Tønnesen HH. Formulation and stability testing of photolabile
drugs. Int J Pharm. 2001;225(1–2):1–14.
22. Li Y, Polozova A, Gruia F, Feng J. Characterization of the degra-
dation products of a color-changed monoclonal antibody:
tryptophan-derived chromophores. Anal Chem. 2014;86(14):
6850–7.
33. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stabil-
ity of proteins in aqueous solution: mechanism and driving forces in
nonnative protein aggregation. Pharm Res. 2003;20(9):1325–36.
34. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB.
Protein–excipient interactions: mechanisms and biophysical char-
acterization applied to protein formulation development. Adv Drug
Deliv Rev. 2011;63(13):1118–59.
35. Ohtake S, Kita Y, Arakawa T. Interactions of formulation exci-
pients with proteins in solution and in the dried state. Adv Drug
Deliv Rev. 2011;63(13):1053–73.
36. Maity H, O'Dell C, Srivastava A, Goldstein J. Effects of arginine on
photostability and thermal stability of IgG1 monoclonal antibodies.
Curr Pharm Biotechnol. 2009;10(8):761–6.
37. Arakawa T, Timasheff S. The mechanism of action of Na gluta-
mate, lysine HCl, and piperazine-N, N'-bis (2-ethanesulfonic acid)
in the stabilization of tubulin and microtubule formation. J Biol
Chem. 1984;259(8):4979–86.
38. Dion MZ, Leiske D, Sharma VK, de Zafra CLZ, Salisbury CM.
Mitigation of oxidation in therapeutic antibody formulations: a
biochemical efficacy and safety evaluation of N-acetyl-tryptophan
and L-methionine. Pharm Res. 2018;35(11):222.
39. Arakawa T, Timasheff SN. Stabilization of protein structure by
sugars. Biochemistry. 1982;21(25):6536–44.
40. Sudrik CM, Cloutier T, Mody N, Sathish HA, Trout BL.
Understanding the role of preferential exclusion of sugars and pol-
yols from native state IgG1 monoclonal antibodies and its effect on
aggregation and reversible self-association. Pharm Res. 2019;36(8):
109–9.
41. Amani M, Barzegar A, Mazani M. Osmolytic effect of sucrose on
thermal denaturation of pea seedling copper amine oxidase.
Protein J. 2017;36(2):147–53.
42. Oshima H, Kinoshita M. Effects of sugars on the thermal stability of
a protein. The Journal of Chemical Physics. 2013;138(24):
06B612_611.
43. Flood A, Estrada M, McAdams D, Ji Y, Chen D. Development of a
freeze-dried, heat-stable influenza subunit vaccine formulation.
PloS One. 2016;11(11).
44. Fischer S, Hoernschemeyer J, Mahler H-C. Glycation during stor-
age and administration of monoclonal antibody formulations. Eur J
Pharm Biopharm. 2008;70(1):42–50.
45. Ouellette D, Alessandri L, Piparia R, Aikhoje A, Chin A,
Radziejewski C, et al. Elevated cleavage of human immunoglobu-
lin gamma molecules containing a lambda light chain mediated by
iron and histidine. Anal Biochem. 2009;389(2):107–17.
23. Subelzu N, Schöneich C. Near UV and visible light induce iron-
dependent photo-degradation reactions in pharmaceutical buffers:
mechanistic and product studies. Mol Pharm. 2020;17(11):4163–
79.
24. Falconer RJ. Advances in liquid formulations of parenteral thera-
peutic proteins. Biotechnol Adv. 2019;37(7):107412.
25. Pramanick S, Singodia D, Chandel V. Excipient selection in par-
enteral formulation development. Pharma Times. 2013;45(3):65–
77.
26. Wlodarczyk SR, Custódio D, Pessoa A Jr, Monteiro G. Influence
and effect of osmolytes in biopharmaceutical formulations. Eur J
Pharm Biopharm. 2018;131:92–8.
27. LeClair DA, Cranston ED, Xing Z, Thompson MR. Evaluation of
excipients for enhanced thermal stabilization of a human type 5